- Home
- Publications
- Publication Search
- Publication Details
Title
Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
American Society of Clinical Oncology (ASCO)
Online
2022-10-21
DOI
10.1200/jco.22.01015
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Low-Dose Nivolumab in Renal Cell Carcinoma: A Real-World Experience
- (2021) Joseph J. Zhao et al. ONCOLOGY
- A real‐world data of Immune checkpoint inhibitors in solid tumors from India
- (2021) Vanita Noronha et al. Cancer Medicine
- The Pattern of Care of Use of Nivolumab in Head and Neck Cancers – Audit From a Tertiary Cancer Centre
- (2021) V.M. Patil et al. CLINICAL ONCOLOGY
- Stability of nivolumab in its original vials after opening and handing in normal saline bag for intravenous infusion
- (2020) G. Le Guyader et al. EUROPEAN JOURNAL OF CANCER
- Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
- (2020) David G. Pfister et al. Journal of the National Comprehensive Cancer Network
- A decade of immune-checkpoint inhibitors in cancer therapy
- (2020) Caroline Robert Nature Communications
- 1049P Efficacy and safety of low dose immunotherapy in palliative setting of advanced solid tumours
- (2020) A. Kumar et al. ANNALS OF ONCOLOGY
- Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial
- (2020) Vijay Patil et al. Lancet Global Health
- Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer
- (2019) Vijay M. Patil et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
- (2019) Akintunde Akinleye et al. Journal of Hematology & Oncology
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
- (2018) Ezra E W Cohen et al. LANCET
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck
- (2015) Vijay Maruti Patil et al. ORAL ONCOLOGY
- Guidelines for treatment of recurrent or metastatic head and neck cancer
- (2014) SH Advani et al. INDIAN JOURNAL OF CANCER
- Epidemiologic Trends in Head and Neck Cancer and Aids in Diagnosis
- (2014) Nadarajah Vigneswaran et al. Oral and Maxillofacial Surgery Clinics of North America
- An Evaluation of Treatment Strategies for Head and Neck Cancer in an African American Population
- (2013) DN Ignacio et al. WEST INDIAN MEDICAL JOURNAL
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More